Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
                
Learn More
Learn More
                                    LOX-1/OLR1 Antibody (331212), mFluor Violet 450 SE, Novus Biologicals™
                                    
                                    
                                    
                                    
                                
                            
                            
                            
                            
Mouse Monoclonal Antibody
Supplier: Novus Biologicals FAB1798MFV450
Description
LOX-1/OLR1 Monoclonal antibody specifically detects LOX-1/OLR1 in Human samples. It is validated for Western Blot, Flow Cytometry, Blocking Assay, CyTOFSpecifications
| LOX-1/OLR1 | |
| Monoclonal | |
| mFluor Violet 450 SE | |
| 50mM Sodium Borate | |
| Mouse | |
| 0.1 mL | |
| Cardiovascular Biology, metabolism | |
| 4973 | |
| Store at 4C in the dark. | 
| Western Blot, Flow Cytometry, Blocking Assay, CyTOF | |
| 331212 | |
| Western Blot, Flow Cytometry, Blockade of Receptor-ligand Interaction, CyTOF-ready | |
| CLEC8ASLOX1, C-type lectin domain family 8 member A, hLOX-1, Lectin-like oxidized LDL receptor 1, Lectin-like oxLDL receptor 1, Lectin-type oxidized LDL receptor 1, LOX-1, LOX1ox LDL receptor 1, LOXIN, oxidised low density lipoprotein (lectin-like) receptor 1, oxidized low density lipoprotein (lectin-like) receptor 1, oxidized low-density lipoprotein receptor 1, oxidized low-density lipoprotein receptor 1, soluble form, Ox-LDL receptor 1, SCARE1, scavenger receptor class E, member 1 | |
| Mouse myeloma cell line NS0-derived recombinant human LOX-1/OLR1, Ser61-Gln273, Accession # P78380 | |
| RUO | |
| Primary | |
| Human | |
| IgG2b | 
                    Product Content Correction
                
                Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
			
            Spot an opportunity for improvement?Share a Content Correction